Dr. Marra Francis Joins Genece Health as Chief Medical Officer [Yahoo! Finance]
GeneDx Holdings Corp. - Class A (WGS)
Company Research
Source: Yahoo! Finance
She is also currently a member of the MIT Catalyst Faculty. Most recently, Dr. Francis was an advisor to Droplet Biosciences and to Exai Bio, where she built their respective target product profiles ahead of Droplet's first product launch and Exai's clinical validation study. At Delphi, she led an early access program for their flagship commercial test. Dr. Francis' past experience also includes serving as head of medical affairs for women's health of Sema4 (now GeneDx); as executive medical director of EverlyWell; and as chief medical officer of Aspira Women's Health. Earlier in her career, she served as both vice chair and chair of the Department of Obstetrics and Gynecology at Memorial Hermann Hospital of the Woodlands. Dr. Francis holds a medical degree from the University of Connecticut Health Center and a bachelor of arts degree in biology from Occidental College. Dr. Marra Francis named as Genece Health CMO “We are delighted to have Marra join our team at a very exciting ti
Show less
Read more
Impact Snapshot
Event Time:
WGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WGS alerts
High impacting GeneDx Holdings Corp. - Class A news events
Weekly update
A roundup of the hottest topics
WGS
News
- GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease DatasetGlobeNewswire
- GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at BTIG Research from $11.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $6.00 to $11.00. They now have a "neutral" rating on the stock.MarketBeat
- GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024GlobeNewswire
- Here's Why GENEDX HOLDINGS (WGS) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]Yahoo! Finance
WGS
Earnings
- 10/30/23 - Miss
WGS
Sec Filings
- 3/19/24 - Form 4
- 3/19/24 - Form 4
- 3/19/24 - Form 4
- WGS's page on the SEC website